3D Medicines

Executive Summary

3D Medicines is an integrated biopharmaceutical company based in Shanghai, China, focused on oncology and immunology. Founded in 2014, the company employs 500-1000 people and has reached the commercial stage. Its unique '3D' strategy combines Drug development, companion Diagnostic tests, and Data analytics to enable personalized cancer treatment. By integrating these three pillars, 3D Medicines aims to improve patient outcomes through precise, data-driven therapies. The company develops novel immuno-oncology drugs while offering diagnostic tests that guide treatment decisions, positioning itself at the forefront of precision medicine in China. As a publicly traded company without a specified ticker, 3D Medicines is navigating the competitive Chinese biopharma landscape. Its commercial-stage status suggests it has at least one approved product or revenue stream, though specific approvals are not disclosed. The company's holistic approach may provide a competitive edge, but risks include regulatory hurdles and market adoption. Looking ahead, 3D Medicines is expected to advance its pipeline of immuno-oncology candidates and expand diagnostic offerings. Key catalysts include potential new drug approvals, clinical trial readouts, and strategic partnerships. The company's success hinges on its ability to execute its integrated model and capture market share in China's growing precision oncology market.

Upcoming Catalysts (preview)

• Q4 2026Approval of a new immuno-oncology drug in China45% success
• Q2 2027Positive Phase 2/3 clinical trial results for lead pipeline candidate55% success
• Q3 2026Strategic partnership for companion diagnostic expansion60% success